OncoMatch/Clinical Trials/NCT06427239
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
Is NCT06427239 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including HRS-4642 and Adebrelimab for pancreatic cancer.
Treatment: HRS-4642 · Adebrelimab — The study is being conducted to evaluate the safety, tolerability and efficacy of HRS-4642 combined with adebelimab in subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard treatment
With failure or absence of standard treatment, and progress within 6 months of adjuvant therapy can also be included in the study
Cannot have received: systemic antitumor therapy
Systemic antitumor therapy was received 4 weeks before the start of the study
Cannot have received: palliative radiotherapy
palliative radiotherapy was completed within 14 days before the first dose
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previously received allogeneic hematopoietic stem cell transplantation
Cannot have received: organ transplantation
Previously received...organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Adequate marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06427239 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic antitumor therapy, palliative radiotherapy, allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages